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Guillain–Barre´ syndrome is divided into two major subtypes, acute inflammatory demyelinating polyneuropathy and acute motor
axonal neuropathy. The characteristic electrophysiological features of acute motor axonal neuropathy are reduced amplitude or
absence of distal compound muscle action potentials indicating axonal degeneration. In contrast, autopsy study results show
early nodal changes in acute motor axonal neuropathy that may produce motor nerve conduction block. Because the presence of
conduction block in acute motor axonal neuropathy has yet to be fully recognized, we reviewed how often conduction block
occurred and how frequently it either reversed or was followed by axonal degeneration. Based on Ho’s criteria, acute motor
axonal neuropathy was electrodiagnosed in 18 patients, and repeated motor nerve conduction studies were carried out on their
median and ulnar nerves. Forearm segments of these nerves and the across-elbow segments of the ulnar nerve were examined
to evaluate conduction block based on the consensus criteria of the American Association of Electrodiagnostic Medicine. Twelve
(67%) of the 18 patients with acute motor axonal neuropathy had definite (n = 7) or probable (n = 5) conduction blocks. Definite
conduction block was detected for one patient (6%) in the forearm segments of both nerves and probable conduction block was
detected for five patients (28%). Definite conduction block was present across the elbow segment of the ulnar nerve in seven
patients (39%) and probable conduction block in two patients (11%). Conduction block was reversible in seven of 12 patients
and was followed by axonal degeneration in six. All conduction blocks had disappeared or begun to resolve within three weeks
with no electrophysiological evidence of remyelination. One patient showed both reversible conduction block and conduction
block followed by axonal degeneration. Clinical features and anti-ganglioside antibody profiles were similar in the patients with
(n = 12) and without (n = 6) conduction block as well as in those with (n = 7) and without (n = 5) reversible conduction block,
indicating that both conditions form a continuum; a pathophysiological spectrum ranging from reversible conduction failure to
axonal degeneration, possibly mediated by antibody attack on gangliosides at the axolemma of the nodes of Ranvier, indicating
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that reversible conduction block and conduction block followed by axonal degeneration and axonal degeneration without
conduction block constitute continuous electrophysiological conditions in acute motor axonal neuropathy.
Keywords: anti-ganglioside antibody; acute motor axonal neuropathy; acute motor conduction block neuropathy; conduction block;
Guillain–Barre´ syndrome
Abbreviations: AIDP = acute inflammatory demyelinating polyneuropathy; AMAN = acute motor axonal neuropathy;
CMAP = compound muscle action potential; GBS = Guillain–Barre´ syndrome; IgG = immunoglobulin G
Introduction
Guillain–Barre´ syndrome (GBS) has two major subtypes, acute
inflammatory demyelinating polyneuropathy (AIDP) and acute
motor axonal neuropathy (AMAN) (McKhann et al., 1993). GBS
is a post-infectious autoimmune disease prototype, AMAN being
associated with antecedent Campylobacter jejuni enteritis and
immunoglobulin G (IgG) autoantibodies against gangliosides
(Ogawara et al., 2000, 2003). Autopsy study results of advanced
AMAN cases show Wallerian-like degeneration of motor fibres
in the spinal nerve roots and peripheral nerves but with
little lymphocytic inflammation or demyelination (McKhann
et al., 1993). Electrophysiological studies have been important in
the diagnosis and classification of these GBS subtypes (Ho et al.,
1995; Hadden et al., 1998). Characteristic features of AMAN
include reduced amplitude or absence of distal compound
muscle action potentials (CMAPs), which suggest axonal
degeneration.
Although most demyelination criteria include conduction block
as a physiological finding—indicative of segmental demyelin-
ation—the phenomenon is not always related to demyelination
(Lewis, 2007). For instance, conduction block is also a local an-
aesthetic mechanism caused by sodium channel function blockage
at the nodes of Ranvier without segmental demyelination. Electron
microscopy studies have shown that the earliest and mildest
changes in AMAN consist of complement deposits at the nodes
of Ranvier, lengthening of the nodes with distortion of paranodal
myelin and in some instances, breakdown of the outermost
myelin terminal loops (Griffin et al., 1996; Hafer-Macko et al.,
1996). This arrangement appears to be stable for some time,
but in many fibres the axon subsequently undergoes Wallerian-
like degeneration. Nodal and paranodal changes may cause the
paralysis seen in some pathologically mild cases by interfering
with impulse conduction. In the early phase these changes may
be reversible, accounting for the rapid recovery of some severely
paralysed patients with AMAN (Ho et al., 1997). In other words,
motor conduction block may occur at an early AMAN stage
and may be followed by axonal degeneration or rapid resolution.
There have been no comprehensive studies showing con-
duction block in AMAN, but reversible conduction failure has
been reported in GBS associated with preceding C. jejuni
infection or IgG anti-ganglioside antibodies (Kuwabara et al.,
1998, 1999, 2004; Hiraga et al., 2005a). Here we retrospectively
report on the frequency of conduction block in patients with
AMAN and how often it is reversible or leads to axonal
degeneration.
Materials and methods
Patients
At Dokkyo Medical University Hospital between April 1999 and
December 2008, one of the authors (NK) performed nerve conduction
studies on 54 patients who fulfilled the clinical criteria for GBS (Asbury
and Cornblath, 1990). Features reviewed included antecedent
infection, clinical symptoms and signs, number of days to nadir,
Hughes functional grade scores (Hughes et al., 1978) at nadir and
clinical outcome. Patients with acute-onset chronic inflammatory
demyelinating polyneuropathy (Ruts et al., 2010) were excluded.
Electrophysiological studies
Nerve conduction studies were done with a Nicolet VIKING IV EMG
machine (CareFusion Japan, Tokyo, Japan). As described elsewhere
(Oh, 2003), CMAPs were recorded from the abductor pollicis brevis
muscle after stimulation of the median nerve at the wrist, elbow and
axilla; the abductor digiti minimi muscle after stimulation of the ulnar
nerve at the wrist, below the elbow, above the elbow and axilla; the
extensor digitorum brevis muscle after stimulation of the peroneal
nerve at the ankle and fibular head; the abductor hallucis muscle
after stimulation of the tibial nerve at the ankle and popliteal fossa.
For CMAP recordings the EMG filter was set at 20 Hz to 20 kHz.
Amplitude, area and duration of the initial negative phase were the
CMAP measurements used. The patients with GBS were divided into
two subtypes, namely AIDP and AMAN, based on Ho’s electrodiagnos-
tic criteria (Ho et al., 1995). We were careful to avoid misdiagnosis
caused by Martin-Gruber anastomosis or other technical failures.
The CMAP parameters determined to evaluate conduction abnorm-
alities in the forearm segment and across the elbow segment were
amplitude decrement (%), calculated as (distal CMAP amplitude –
proximal CMAP amplitude)  100/(distal CMAP amplitude); area dec-
rement (%), calculated as (distal CMAP area – proximal CMAP area)
 100/(distal CMAP area); and temporal dispersion (%), calculated as
(proximal CMAP duration/distal CMAP duration)  100. Based on the
consensus criteria of the American Association of Electrodiagnostic
Medicine (Olney, 1999), definite partial conduction block was defined
as an amplitude decrement of more than 50% with530% temporal
dispersion. Probable partial conduction block was defined as an
amplitude decrement of 40–49% with 530% temporal dispersion.
These criteria were applied only to a nerve in which the distal
CMAP amplitude was 20% or more of the lower limit of normal.
Furthermore, based on changes in serial recordings, conduction
blocks were classified into two groups; reversible conduction failure
and length-dependent conduction failure. Reversible conduction failure
was defined as conduction block being resolved quickly with no
development of excessive temporal dispersion or other demyelination
features (Kuwabara et al., 1998, 1999). Length-dependent conduction
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failure was defined as the disappearance of conduction block due to
progressive reduction of distal CMAP amplitude.
Initial examinations were made on the day of admission and
follow-up studies between 2 and 14 weeks after disease onset.
Stimulus duration was 0.2 ms in all the examinations, with intensity
ranging from 20–100 mA to obtain supramaximum stimulation. Skin
temperature was maintained above 32C. Normal values were ob-
tained from 48 healthy subjects, mean age 42 years (range
19–81 years). For distal motor latency, CMAP duration and conduction
velocity, any value falling outside 2.5 standard deviations (SD) of the
control mean was considered abnormal. CMAP amplitude abnormality
was taken to be a value52.5 SD of the mean of the logarithmically
transformed amplitude of the controls.
Electrophysiological demyelination features were a distal motor
latency of more than 4.8 ms (or more than 5.3 ms if the distal CMAP
amplitude was52.4 mV) in the median nerve and more than 4.0 ms
(or more than 4.3 ms if the distal CMAP amplitude was52.0 mV) in
the ulnar nerve. For conduction velocity, it was a value 545 m/s
(or543 m/s if the distal CMAP amplitude was52.4 mV) in the median
nerve and 546 m/s (or 544 m/s if the distal CMAP amplitude was
52.0 mV) in the ulnar nerve. Based on Ho’s criteria (Ho et al., 1995),
axonal degeneration was defined as a distal CMAP amplitude of580% of
the lower normal limit, and53.8 mV in the median nerve and 3.3 mV in
the ulnar nerve. Distal nerve demyelination was defined as a distal CMAP
duration of more than 6.6 ms in the median and 6.7 ms in the ulnar nerve
(Isose et al., 2009).
Serological studies
Serum IgG and IgM antibodies to the gangliosides GM1, GM1b,
GD1a, GalNAc–GD1a, GD1b, GT1a and GQ1b were measured by
an enzyme-linked immunosorbent assay, as described elsewhere
(Yuki et al., 1997). In the present study, serum was considered posi-
tive when the optical density was 0.5 or more at a 1:500 dilution. IgG
antibodies to at least one combination of two of the seven ganglio-
sides (GM1, GM2, GD1a, GD1b, GT1a, GT1b and GQ1b, each
5 pmol/well) were determined. Anti-ganglioside complex antibodies
were judged positive when the optical density was 0.5 greater than
the sum of the antibodies against each ganglioside.
Statistical analyses
Differences in medians were examined by the Mann-Whitney U-test
using statistical software (SPSS 12.0J; SPSS Inc, Chicago, Illinois).
Differences in frequencies between groups were compared by the
2 or Fisher exact test (two-tailed). A difference of P50.05 was
considered statistically significant.
Results
Electrodiagnostic classification
This classification was based on conventional motor nerve
conduction studies of the median, ulnar, peroneal and tibial nerves.
The 54 patients with GBS underwent the first electrophysiological
study 2–16 days (median 6 days) after onset of symptoms. Test
results showed 19 AIDP (35%), 13 AMAN (24%) and 22 equivocal
(13 unclassifiable and nine normal) patients (Fig. 1). Follow-up study
results however, reclassified them as 14 AIDP (26%) and 31 AMAN
(57%) patients. Five of nine patients who finally were classified
‘equivocal’ did not undergo follow-up studies at the appropriate
times. Sensory nerve conduction studies were normal in all AMAN
patients but one who had diminished sensory nerve action potentials
(Patient 18), for whom acute motor sensory axonal neuropathy was
the diagnosis.
Because 18 of the 31 patients with AMAN had undergone
conduction studies of both the forearm and elbow segments,
further electrophysiological recordings were reviewed selectively.
The 18 patients received two or more examinations during the
2 months after disease onset. Neither the clinical nor serological
features differed significantly for these 18 and the other
13 patients with AMAN.
Distal compound muscle action
potential
Nerve conduction studies were done on 16 of the 18 patients
within 7 days of disease onset. During week 1, distal CMAP
amplitudes were within the normal range in eleven patients
(69%, Patients 1, 2, 4, 6, 8, 9, 10, 11, 12, 13 and 14), in the
median nerve and in nine patients (60%, Patients 1, 2, 3, 6, 8, 9,
10, 13 and 17) in the ulnar nerve (Fig. 2A). Axonal degeneration
was present in only five patients in the median nerve and in four
patients (27%) in the ulnar nerve. At disease nadir (median 7
days, range 3–13 days), decreases in CMAPs were observed in
all patients as compared with earlier study or recovery stage data.
In the early disease stage, prolonged distal motor latencies in the
median nerve that fulfilled demyelination criteria were present in
five of the 18 patients (Patients 2, 8, 9, 11 and 17); whereas distal
motor latencies in the ulnar nerve were normal in all 18 patients
(Table 1). Four of those five patients had prolonged distal motor
latency in one median nerve, and one had it bilaterally (Patient 9).
Serial nerve conduction studies showed rapid recovery without pro-
longed distal CMAP duration in Patient 9 and rapid improvement
in distal motor latency with only residual minimal prolongation in
Figure 1 Serial electrodiagnostic subtype changes in 54 patients
with GBS. Arrows indicate direction of change from one subtype
to another. Numbers indicate the patients changing group.
Equivocal refers to electrodiagnostically normal and unclassifiable
groups. Initially 22 patients were classified as equivocal. Eleven
were later re-classified as having AMAN. Seven patients with GBS
who, at first had prolonged distal motor latencies, eventually
developed AMAN.
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Patients 2, 8, 11 and 17 at follow-up. None had prolonged distal
CMAP durations that fulfilled the criteria for distal demyelination in
either nerve during the course of the illness.
Compound muscle action potential
amplitude decrement
Twelve of the 18 patients (67%) had probable or definite
conduction block. With respect to the forearm segments,
conduction block was definite for one patient (6%, Patient 14)
in the median nerve, probable for two patients (11%, Patients 12
and 17) in the median nerve and for three patients (16%, Patients
2, 7 and 8) in the ulnar nerve. A common entrapment site (across
the elbow segment of the ulnar nerve) showed definite conduction
block in seven patients (39%, Patients 1, 3, 7, 9, 14, 15 and 18)
and probable conduction block in two patients (11%, Patients 11
and 17). In four (Patients 1, 9, 14 and 15) of these seven patients,
bilateral definite conduction blocks were observed. The time from
disease onset in the first study of the 12 patients with AMAN who
Figure 2 Serial changes in motor conduction abnormalities. Recordings show superimposed CMAPs from the abductor pollicis brevi
stimulated at the wrist, elbow and axilla in the median nerve, and from the abductor digiti minimi at the wrist, below the elbow, above the
elbow and axilla in the ulnar nerve. (A) Typical AMAN (Patient 13). On Day 3 CMAPs have normal amplitudes. A progressive decrease in
CMAP amplitude is present at follow-up. (B) AMAN with reversible conduction failure (Patient 15). On Day 8 definite conduction block is
present across the elbow segment of the ulnar nerve but CMAP amplitudes in the median nerve are within normal limits. Subsequently,
conduction block has been resolved rapidly with no excessive temporal dispersion. CMAP amplitudes in the median nerve are decreased
transiently on Day 12 and restored on Day 25. (C) AMAN with length-dependent conduction failure (Patient 3). On Day 2 a marked
CMAP amplitude decrease is seen in the median nerve, and definite conduction block is present across the elbow segment of the ulnar
nerve. A subsequent, progressive decrease in distal CMAPs is seen at follow-up. (D) AMAN with reversible and length-dependent
conduction failure (Patient 1). On Day 3 CMAPs in the median and ulnar nerves are within the normal range but with mild amplitude
reduction of CMAP across the elbow segment of the ulnar nerve. On Day 6 CMAPs are decreased in the median nerve and definite
conduction block is present in the ulnar nerve. On Day 22 CMAPs have recovered in the median nerve but decreased progressively in the
ulnar nerve. Conduction block in the ulnar nerve is lessened because of the proximal CMAP increase and distal CMAP amplitude decrease.
(E) AIDP. On Day 8, slight amplitude reduction of proximal CMAP is present across the elbow segment. Although clinical symptom nadir
occurred on Day 10, conduction abnormalities worsened over 2 months. Distal motor latency was 8.1 ms and distal CMAP duration
10.1 ms on Day 74. CMAPs gradually improved with marked prolongation of distal motor latencies, conduction slowing and excessive
temporal dispersion, especially across the elbow segment. Asterisk denotes nerves not stimulated at the axilla; L = left; R = right.
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had conduction block (median 3 days, range 2–8 days) was similar
to that in the six who did not (median 5 days, range 3–11 days,
P= 0.207).
On sequential evaluation, rapid resolution was found in seven
(58%, Patients 1, 9, 11, 12, 14, 15 and 18) of the 12 patients
who had probable or definite conduction block (Table 1 and
Fig. 2B). No excessive temporal dispersion of proximal CMAPs
was found during the recovery period. Conduction block was
resolved after intravenous immunoglobulin therapy or plasma ex-
change in six of the seven patients and in one (Patient 15) who
refused immunotherapy and showed spontaneous recovery. These
patients’ conditions fulfilled the definition of reversible conduction
failure.
In five patients (42%, Patients 2, 3, 7, 8 and 17), distal CMAP
amplitudes decreased, becoming comparable to those of proximal
CMAPs with the disappearance of conduction block, but without
development of excessive temporal dispersion or other features of
demyelination (Fig. 2C). Those patients’ conditions fulfilled the
definition of length-dependent conduction failure. All the abnor-
mal CMAP amplitude decrements were detected during the
3 weeks after disease onset. Reversible conduction failure and
length-dependent conduction failure patterns were present in
the ulnar nerve of Patient 1 (Fig. 2D). Table 1 shows the area
decrement (%) and amplitude decrement (%) in the patients who
showed conduction block.
Conduction velocities
The initial study of one patient (Patient 12) showed conduction slow-
ing in forearm segments of the median (43 m/s) and ulnar (46 m/s)
nerves, fulfilling demyelination criteria, but which on follow-up
quickly returned to the normal range. Abnormal amplitude decre-
ments were present in these segments. The across-elbow segment of
the ulnar nerve showed conduction slowing in 13 of the 18 patients
with AMAN with and without conduction block (mean 45 m/s; range
31–68 m/s). In the follow-up study, slight conduction slowing still
remained in nine patients.
Clinical features
Table 2 shows clinical profiles of the 14 AIDP and 31 AMAN
patients. Age distribution did not differ significantly between the
groups. Females predominated in AIDP, males in AMAN, but the
difference did not reach statistical significance. In contrast, diar-
rhoea preceded AMAN significantly more often than it did AIDP
[P= 0.004; odds ratio (OR) 9.5; 95% confidence interval (CI)
1.80–50.08]. Facial weakness (P= 0.007; OR 0.14; 95% CI
0.03–0.57) and sensory signs (P= 0.028; OR 0.20; 95% CI
0.05–0.85) were less common in AMAN. Median number of
days to nadir was significantly shorter in AMAN (P= 0.015).
Patients who required endotracheal intubation (P= 0.049; OR
0.20; 95% CI 0.04–0.89) or mechanical ventilation (P= 0.007;
OR 0.09; 95% CI 0.02–0.55) were significantly fewer in the
AMAN than AIDP group.
Age distribution, sex ratio, antecedent diarrhoea, progression
period and the Hughes grade score at nadir did not differ signifi-
cantly between the AMAN subgroups with and without
conduction block (Table 2). Nor did they differ between the
AMAN subgroups with reversible conduction failure and length-
dependent conduction failure. Hughes grade scores at discharge
for patients with AMAN with reversible conduction failure were
significantly milder than for the group with length-dependent
conduction failure (P= 0.010; OR 20.0; 95% CI 1.42–282.45).
None of the 31 patients with AMAN showed treatment-related
fluctuations (Ruts et al., 2010), but two of the patients (Patients 4
and 17) received additional intravenous immunoglobulin therapy
because of poor recovery.
Serological studies
Of the 31 patients with AMAN, 29 (94%) had one or more
anti-ganglioside IgG antibodies tested and 6 (19%) had IgM anti-
bodies tested. The IgG anti-ganglioside antibodies frequently pre-
sent were against GM1 (61%), GM1b (52%) and GD1b (42%).
Frequencies of the anti-ganglioside antibody did not differ be-
tween the AMAN subgroups with and without conduction block
or between those with reversible and length-dependent conduc-
tion failure. The presence of IgG antibodies against ganglioside
complex was examined in the 18 patients with AMAN who under-
went detailed follow-up studies. There were no significant differ-
ences between the presence of conduction block or reversible
conduction failure and any of the anti-ganglioside complex anti-
bodies (Table 3). Antibodies to the GM1/GalNAc–GD1a complex
were detected in two patients with AMAN who had conduction
block (Patients 1 and 7). One showed reversible conduction fail-
ure, the other length-dependent conduction failure.
Discussion
The term AMAN originates from pathology studies but currently it
is diagnosed by electrophysiological testing. Autopsy studies show
deposits of IgG and complement at the nodal and internodal
axolemma in patients with AMAN, which produce minimal nodal
changes to severe axonal degeneration (McKhann et al., 1993;
Hafer-Macko et al., 1996). In contrast, electrodiagnostic criteria
for this GBS subtype are based on the assumption that AMAN
causes only axonal degeneration (Ho et al., 1995; Hadden
et al., 1998). In the early disease phase some patients with
anti-ganglioside antibodies have nerves with reduced distal
CMAP amplitudes and prolonged distal motor latencies and
nerves with conduction block at common entrapment sites
mimicking demyelination features (Kuwabara et al., 1998, 1999).
At follow-up some patients showed persistently reduced or distal
CMAP absence; whereas others showed rapid normalization of
their distal CMAP amplitudes, distal motor latencies and conduc-
tion block recovery without development of temporal dispersion or
increased latency. These findings were thought to be incompatible
with demyelination and remyelination, indicating that AMAN is
characterized not only by axonal degeneration but also by revers-
ible conduction failure, possibly induced by anti-ganglioside anti-
bodies at the axolemma of the Ranvier nodes (Kuwabara et al.,
1998, 1999). These studies and hypotheses prompted us to
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investigate the frequency of conduction block and its time course
in AMAN.
Of our 18 patients whose final classification was AMAN,
12 (67%) had definite or probable conduction block. Six patients
had conduction block in their forearm segments and nine across
their elbow segments. Conduction block is the term used to
describe the condition in which saltatory conduction is stopped
but the axon remains intact. In practice, it is recognized by an
abnormal amplitude/area CMAP reduction on proximal stimulation
as compared with CMAP on distal stimulation. Conduction block
is usually considered to be the electrophysiological correlate of
segmental demyelination. In the early disease stage and based
on only one recording, no electrodiagnostical distinction between
demyelinating conduction block and other causes of abnormal
amplitude reduction of proximal CMAP, such as reversible
conduction failure and length-dependent conduction failure, is
possible. Observation of serial electrophysiological changes is
important for determining the pathophysiological origin of abnor-
mal CMAP amplitude reduction in GBS subtypes. The concept of
reversible conduction failure encompasses the rapid recoveries of
prolonged distal motor latencies, reduced distal CMAP amplitudes
and conduction block, none of which are explained by remyelina-
tion (Kuwabara et al., 1998, 1999). In contrast, resolution of
demyelinative conduction block in AIDP is usually associated in
serial recordings with conduction slowing and increased CMAP
duration with remyelinating slow components (Albers and Kelly,
1989) (Fig. 2E). At follow-up, 7 of 12 patients with AMAN and
conduction block had a reversible conduction failure pattern and
six had a length-dependent conduction failure pattern. None had
features characteristic of a remyelinating pattern. Length-
dependent conduction failure may be caused by one or more
mechanisms: Wallerian degeneration that has reached the prox-
imal stimulus site but not the distal site; conduction block that
occurred at first, followed by axonal degeneration; or conduction
block that came first and adjunctive axonal degeneration that
occurred in the distal nerve terminals. As any distinction between
these conditions is impossible, we have defined them all as
length-dependent conduction failure and consider this pattern to
be an expression of axonal damage (Uncini et al., 2010b).
Early reversible conduction failure in AMAN is thought to be
induced by anti-GM1 antibodies, possibly due to sodium channel
damage, but this is controversial (Takigawa et al., 1995; Hirota
et al., 1997). An immunohistochemical study of AMAN rabbits
developed by sensitization with GM1 has shown sequential patho-
logical changes starting with IgG deposits at the nodes of Ranvier
(Susuki et al., 2007). The bound antibodies activate complement
resulting in the formation of a membrane attack complex at the
nodal axolemma, disruption of the nodal sodium channel cluster,
lengthening of the nodal region and detachment of paranodal
myelin terminal loops, as detected in patients with AMAN
(Griffin et al., 1996; Hafer-Macko et al., 1996). The last feature
mimics paranodal demyelination, but the primary pathology is
on the axonal side. All these changes lower the safety factor
for impulse transmission which induces potentially reversible
conduction failure. If autoimmune attack progresses, axonal
damage and Wallerian degeneration develop. Interestingly, revers-
ible conduction failure and length-dependent axonal degeneration
patterns coexisted in the same nerve of one of our patients with
AMAN (Patient 1) (Fig. 2D). In this patient, CMAPs in the median
nerve were reduced on Day 6 but had recovered by Day 22,
which suggests early reversible conduction failure at the distal
nerve terminal. In contrast, distal CMAP in the ulnar nerve
decreased progressively during the follow-up period, which sug-
gests length-dependent conduction failure and, at the same time,
conduction block and rapid resolution of conduction block
occurred across the elbow segment. Moreover, the majority of
patients with reversible conduction failure also had slightly reduced
distal CMAPs in the early stage compared with values at follow-up
(which may be considered distal reversible conduction failure)
(Fig. 2D). These findings indicate that the pathophysiological
process in AMAN varies from mild axonal functional involvement
expressed as a reversible conduction failure pattern to axonal
degeneration expressed as length-dependent conduction failure
or distal CMAP reduction and that these conditions are on a
continuous spectrum.
Conduction blocks were present more often across the elbow
segment of the ulnar nerve than across the forearm segments.
Since the majority of our patients with conduction block could
Table 3 Anti-ganglioside complex antibodies in 18 patients with AMAN
IgG antibodies to AMAN AMAN AMAN AMAN with AMAN with AMAN with
with CB
(n = 12)
without CB
(n = 6)
with CB versus
without CB
RCF
(n = 7)
LDCF
(n = 5)
RCF versus LDCF
Two-tailed
Two-tailed
P-value
P-value
GM1/GM1b 2 (17) 0 (0) 0.529 1 (14) 1 (20) 40.99
GM1/GM2 3 (25) 0 (0) 0.515 1 (14) 2 (40) 0.523
GM1/GalNAc–GD1a 2 (17) 0 (0) 0.529 1 (14) 1 (20) 40.99
GM1/GT1a 2 (17) 0 (0) 0.529 0 (0) 2 (40) 0.152
GM1/GT1b 3 (25) 0 (0) 0.515 2 (28) 1 (20) 40.99
GM1/GQ1b 3 (25) 0 (0) 0.515 2 (28) 1 (20) 40.99
GM1b/GM2 2 (17) 0 (0) 0.529 2 (28) 0 (0) 0.470
GQ1b/GT1b 3 (25) 1 (17) 40.99 2 (28) 1 (20) 40.99
CB = partial conduction block; LDCF = length-dependent conduction failure; RCF = reversible conduction failure. Data are given as number (percentage) unless otherwise
indicated.
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move their arms freely, it is unlikely that all the conduction blocks
were due to nerve compression. Several investigators have re-
ported that the conduction abnormalities in GBS tend to be pre-
sent at the distal nerve terminals, nerve roots and common
entrapment sites of the peripheral nerves, where the blood-nerve
barrier is thought to be relatively deficient or weak (Brown and
Snow, 1991; Kuwabara et al., 1998, 1999). In addition, conduc-
tion blocks across the elbow segment were present in the majority
of the patients with GBS in Table 4 when the examinations includ-
ing the elbow segment were done. Our study confirmed these
results and showed that the conduction abnormalities at the
common entrapment sites are a characteristic neurophysiologic
feature observed in AMAN.
In 2003, Capasso et al., reported two peculiar patients who
developed acute symmetric weakness without sensory symptoms
(Capasso et al., 2003). Both had experienced antecedent diar-
rhoea (C. jejuni was isolated from one) and had high IgG antibody
titres to GM1, GD1a and GD1b. Electrophysiological studies
showed reduced distal CMAP amplitudes, early partial motor
conduction block in their forearm segments and normal sensory
conduction, even across the motor conduction block sites. Distal
CMAP amplitudes became normalized. Conduction block was
resolved in 2–5 weeks, as was muscle weakness, without devel-
opment of excessive temporal dispersion of distal or proximal
CMAPs. Capasso et al. (2003) proposed the term ‘acute motor
conduction block neuropathy’ as being another GBS variant.
Similar cases have been reported as atypical GBS (Susuki et al.,
2001; Ferna´ndez-Torre et al., 2008; Manganelli et al., 2009;
Ogawa et al., 2009) or as an acute variant of multifocal motor
neuropathy (White et al., 1996; Wo¨hrle et al., 1996; Abbruzzese
et al., 1997; Sugie et al., 1998; Lefaucheur et al., 2003) (Table 4).
Most of the patients with acute symmetrical presentation, who
had a monophasic course with fast recovery as well as diarrhoea
and evidence of C. jejuni and an IgG antibody isotype of an
anti-GM1 antibody, should be classified as GBS subtypes (White
et al., 1996; Susuki et al., 2001, Capasso et al., 2003; Rajabally
et al., 2006; Kaida et al., 2008). Some patients, who had a more
prolonged course or clinical relapses, presented persistent motor
conduction block and had an autoantibody IgM isotype, possibly
had acute presentation of multifocal motor neuropathy
(Abbruzzese et al., 1997; Lefaucheur et al., 2003; Manganelli
et al., 2009; Uncini et al., 2010a). In our study, two (11%) of
the 18 patients with AMAN had reversible conduction block in the
forearm segment, as in acute motor conduction block neuropathy.
Four patients (22%) had conduction block followed by axonal
degeneration, as in the case reported by Rajabally et al. (2006).
The foregoing observations suggest that acute motor conduction
block neuropathy and AMAN are correlated pathophysiologically
and that acute motor conduction block neuropathy is a mild form
of AMAN, characterized by reversible conduction failure in all
nerves (Uncini and Yuki, 2009).
Patients with GBS associated with anti-GM1, -GM1b or
-GalNAc–GD1a antibodies more frequently have had preceding
C. jejuni infection and less frequently cranial nerve involvement
and sensory disturbance than patients without anti-ganglioside
antibodies (Jacobs et al., 1996; Ang et al., 1999; Yuki et al.,
2000). In our study, as compared with AIDP, patients with
AMAN more often had antecedent diarrhoea, but facial weakness
and sensory signs were less common. We confirmed previous
findings that patients with AMAN have a shorter disease progres-
sion, an earlier nadir and need artificial ventilation less often
(Hiraga et al., 2003, 2005a). These clinical features did not
differ between AMAN subgroups with and without conduction
block or reversible conduction block. Moreover, anti-ganglioside
antibody profiles did not differ between the subgroups. In sum-
mary, the similar clinical and serological features of the subgroups
support the supposition that early reversible conduction failure,
length-dependent conduction failure and axonal degeneration
without conduction block constitute continuous conditions.
Of our 54 patients with GBS, 24% were classified as having
AMAN in the initial studies. Recognition of the reversible conduc-
tion failure and length-dependent conduction failure patterns
changed the classification to 57% at the follow-up. This confirms
that repeated studies help in making an AMAN electrodiagnosis
(Kuwabara et al., 2004; Hiraga et al., 2005b; Uncini et al.,
2010b). Furthermore, 61% of those with the final AMAN diagno-
sis had the IgG anti-GM1 antibody and 94% had at least one of
IgG anti-ganglioside antibodies tested. Our study confirms the
close association of AMAN with antecedent diarrhoea and the
IgG anti-GM1, -GM1b and -GD1b antibodies (Ogawara et al.,
2000, 2003). Kaida et al. (2008) studied 10 patients with GBS
who had IgG antibodies to the GM1/GalNAc–GD1a complex.
Clinical findings for those 10 patients were characterized by a
preserved sensory system and infrequent cranial nerve deficits.
Based on Ho’s criteria (Ho et al., 1995), four patients had the
AIDP pattern, three the AMAN pattern, and five early motor
conduction block in their forearm segments. Kaida et al. (2008)
proposed that GM1 and GalNAc–GD1a form a complex in the
axolemma at the nodes of Ranvier or the paranodes of the
motor nerves and that the complex is a target antigen in pure
motor GBS, especially in acute motor conduction block neur-
opathy. Two of our patients with AMAN with conduction block
had IgG antibodies to the GM1/GalNAc–GD1a complex; whereas
none of the patients with AMAN without conduction block had
them. One of the two showed reversible conduction block, the
other conduction block followed by axonal degeneration. These
findings do not fully support the speculation that GM1/GalNAc–
GD1a is a specific target for autoantibodies in acute motor
conduction block neuropathy.
In conclusion, our study shows that AMAN often presents con-
duction block during the first 3 weeks of illness and frequently
shows reversible conduction failure as well as length-dependent
conduction failure. This may create confusion in making early
electrodiagnoses of GBS subtypes lead to underestimation of
AMAN diagnoses. Serial neurophysiological examinations are
useful for understanding GBS pathophysiology and for obtaining
a true AMAN electrodiagnosis.
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